172 related articles for article (PubMed ID: 35352483)
1. Efficacy of topical steroids for the treatment of olfactory disorders caused by COVID-19: A systematic review and meta-analysis.
Kim DH; Kim SW; Kang M; Hwang SH
Clin Otolaryngol; 2022 Jul; 47(4):509-515. PubMed ID: 35352483
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy of Olfactory Training as a Treatment for Olfactory Disorders Caused by Coronavirus Disease-2019: A Systematic Review and Meta-Analysis.
Hwang SH; Kim SW; Basurrah MA; Kim DH
Am J Rhinol Allergy; 2023 Jul; 37(4):495-501. PubMed ID: 36635974
[TBL] [Abstract][Full Text] [Related]
3. Intranasal Corticosteroid Treatment on Recovery of Long-Term Olfactory Dysfunction Due to COVID-19.
Hosseinpoor M; Kabiri M; Rajati Haghi M; Ghadam Soltani T; Rezaei A; Faghfouri A; Poustchian Gholkhatmi Z; Bakhshaee M
Laryngoscope; 2022 Nov; 132(11):2209-2216. PubMed ID: 36054369
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic use of steroids in non-chronic rhinosinusitis olfactory dysfunction: a systematic evidence-based review with recommendations.
Yan CH; Overdevest JB; Patel ZM
Int Forum Allergy Rhinol; 2019 Feb; 9(2):165-176. PubMed ID: 30472771
[TBL] [Abstract][Full Text] [Related]
5. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction.
Webster KE; O'Byrne L; MacKeith S; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013877. PubMed ID: 34291812
[TBL] [Abstract][Full Text] [Related]
6. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction.
Webster KE; O'Byrne L; MacKeith S; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD013877. PubMed ID: 36063364
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Efficacy of Nasal Corticosteroids in COVID-19-Related Olfactory Dysfunction: A Comprehensive Systematic Review and Meta-analysis.
Chen RD; Yang CW; Chen XB; Hu HF; Cui GZ; Zhu QR; Kuang MJ
Otolaryngol Head Neck Surg; 2024 Apr; 170(4):999-1008. PubMed ID: 38124278
[TBL] [Abstract][Full Text] [Related]
8. Management of Post-Infectious Anosmia and Hyposmia: A Systematic Review.
Nag AK; Saltagi AK; Saltagi MZ; Wu AW; Higgins TS; Knisely A; Ting JY; Illing EA
Ann Otol Rhinol Laryngol; 2023 Jul; 132(7):806-817. PubMed ID: 35959948
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroid nasal irrigation as early treatment of olfactory dysfunction in COVID-19: A prospective randomised controlled trial.
Tragoonrungsea J; Tangbumrungtham N; Nitivanichsakul T; Roongpuvapaht B; Tanjararak K
Clin Otolaryngol; 2023 Mar; 48(2):182-190. PubMed ID: 36336851
[TBL] [Abstract][Full Text] [Related]
10. Alpha-lipoic acid does not improve olfactory training results in olfactory loss due to COVID-19: a double-blind randomized trial.
Figueiredo LP; Paim PVDSL; Cerqueira-Silva T; Barreto CC; Lessa MM
Braz J Otorhinolaryngol; 2024; 90(1):101356. PubMed ID: 37944311
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiological relationship between COVID-19 and olfactory dysfunction: A systematic review.
Las Casas Lima MH; Cavalcante ALB; Leão SC
Braz J Otorhinolaryngol; 2022; 88(5):794-802. PubMed ID: 33965353
[TBL] [Abstract][Full Text] [Related]
13. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
O'Byrne L; Webster KE; MacKeith S; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD013876. PubMed ID: 36062970
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Olfactory Dysfunction in Coronavirus Disease 2019 (COVID-19): A Meta-analysis of 27,492 Patients.
Saniasiaya J; Islam MA; Abdullah B
Laryngoscope; 2021 Apr; 131(4):865-878. PubMed ID: 33219539
[TBL] [Abstract][Full Text] [Related]
15. COCOS trial:
Schepens EJA; Boek WM; Boesveldt S; Stegeman I; Stokroos RJ; Kamalski DMA
BMJ Open; 2022 Aug; 12(8):e060416. PubMed ID: 35948382
[TBL] [Abstract][Full Text] [Related]
16. Olfactory outcomes in chronic rhinosinusitis with nasal polyposis after medical treatments: a systematic review and meta-analysis.
Banglawala SM; Oyer SL; Lohia S; Psaltis AJ; Soler ZM; Schlosser RJ
Int Forum Allergy Rhinol; 2014 Dec; 4(12):986-94. PubMed ID: 25400017
[TBL] [Abstract][Full Text] [Related]
17. Effects of classical olfactory training in patients with COVID-19-related persistent loss of smell.
Yaylacı A; Azak E; Önal A; Aktürk DR; Karadenizli A
Eur Arch Otorhinolaryngol; 2023 Feb; 280(2):757-763. PubMed ID: 35904631
[TBL] [Abstract][Full Text] [Related]
18. Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial.
Kasiri H; Rouhani N; Salehifar E; Ghazaeian M; Fallah S
Int Immunopharmacol; 2021 Sep; 98():107871. PubMed ID: 34147912
[TBL] [Abstract][Full Text] [Related]
19. Corticosteroids for COVID-19-induced olfactory dysfunction: A comprehensive systematic review and meta-analysis of randomized controlled trials.
Wang JY; Pao JB; Lee CH; Wang JY; Lee MC; Wu TT
PLoS One; 2023; 18(12):e0289172. PubMed ID: 38127940
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and meta-analysis protocol examining the clinical characteristics and epidemiological features of olfactory dysfunction (OD) in coronavirus disease 2019 (COVID-19).
Tan RQ; Li WTV; Shum WZ; Chu SC; Li HL; Shea YF; Chung TW
Syst Rev; 2021 Mar; 10(1):73. PubMed ID: 33691796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
